Spots Global Cancer Trial Database for kras wild type
Every month we try and update this database with for kras wild type cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | NCT01508000 | Colorectal Canc... Liver Metastase... KRAS Wild Type ... | FOLFOX6 Bevacizumab Panitumumab Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma | NCT01351038 | KRAS Wild Type Resectable Type... | Epirubicine, Ox... | 18 Years - 65 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| Biomarker - Panitumumab Response With KRAS Wild Type MCC | NCT00853931 | Metastatic Colo... | Panitumumab | 18 Years - | British Columbia Cancer Agency | |
| Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient | NCT02295930 | Metastatic Colo... | folfoxiri+cetux... folfoxiri+cetux... | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma | NCT01351038 | KRAS Wild Type Resectable Type... | Epirubicine, Ox... | 18 Years - 65 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | NCT01504477 | Colorectal Canc... | Panitumumab and... | 18 Years - | Georgetown University | |
| Colorectal Cancer (CRC) Cetuximab Elderly Frail | NCT01522612 | Colorectal Canc... | Cetuximab 5-fluorouracil leucovorin | 70 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma | NCT01351038 | KRAS Wild Type Resectable Type... | Epirubicine, Ox... | 18 Years - 65 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | NCT00803647 | Metastatic Colo... | cetuximab 5-FU oxaliplatin leucovorin | 18 Years - | NSABP Foundation Inc | |
| Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient | NCT02295930 | Metastatic Colo... | folfoxiri+cetux... folfoxiri+cetux... | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
